2seventy Bio jumps 11% on release of positive results in KarMMa-3 study

Shares of 2seventy Bio are up 11% afterhours at $10.96 following the company’s regulatory 8-K filing, stating: "On January 4, 2023, the EBMT-EHA released an abstract previously submitted by 2seventy bio (TSVT) and Bristol Myers Squibb (BMY) for presentation at the EBMT-EHA 5th European CAR T-cell meeting. The abstract, available on the EBMT-EHA website, includes key data points from the positive results of the Registrant’s KarMMa-3 study of ABECMA, idecabtagene vicleucel. Results from KarMMa-3, a pivotal Phase 3, open-label, global, randomized, controlled study evaluating ABECMA compared to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and were refractory to their last regimen. Ide-cel significantly improved progression-free survival versus standard regimens. Overall response rate was significantly improved with ide-cel versus standard regimens, 71% vs 42%, with deeper, more durable responses. Full results from the KarMMa-3 study will be presented at the EBMT-EHA 5th European CAR T-cell meeting, taking place from February 8-11, 2023, in Rotterdam, Netherlands."